Single Patient Expanded Access Protocol: Metabolic Boost

A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen

NCT00427661 ·Status: COMPLETED ·Phase: NA

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863 ·Status: RECRUITING ·Phase: PHASE1

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962 ·Status: COMPLETED ·Phase: PHASE2

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

NCT01242267 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

NCT00006056 ·Status: UNKNOWN ·Phase: NA

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

NCT00253552 ·Status: TERMINATED ·Phase: NA

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

NCT01565616 ·Status: COMPLETED ·Phase: PHASE2

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

NCT05732961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

NCT00668564 ·Status: TERMINATED ·Phase: PHASE2

Stem Cell Transplant for Hemoglobinopathy

NCT00176852 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003960 ·Status: COMPLETED ·Phase: PHASE2

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

NCT00047268 ·Status: UNKNOWN ·Phase: PHASE3

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

NCT00923364 ·Status: COMPLETED ·Phase: PHASE2

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

NCT02251821 ·Status: COMPLETED ·Phase: PHASE2

JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders

NCT00873574 ·Status: COMPLETED

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

NCT00520468 ·Status: COMPLETED ·Phase: PHASE2

Gene Therapy for Wiskott-Aldrich Syndrome (WAS)

NCT01347242 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

NCT00453206 ·Status: COMPLETED ·Phase: NA

Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

NCT02763033 ·Status: COMPLETED ·Phase: PHASE2

Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis

NCT00578435 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

NCT00695396 ·Status: TERMINATED ·Phase: PHASE3

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

NCT01026987 ·Status: COMPLETED ·Phase: PHASE1

Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)

NCT00231309 ·Status: COMPLETED ·Phase: NA

Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

NCT03427866 ·Status: COMPLETED ·Phase: PHASE2

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

NCT02248597 ·Status: COMPLETED ·Phase: PHASE2